Accelerated progress of clinical trials will ultimately result in the development and commercialization of new drugs targeting rare as well as commonly inherited diseases. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, acute leukemia that has been historically difficult to diagnose. In December 2018, Tagraxofusp became the first therapy approved for treating BPDCN, which then became the standard care method. During clinical trials, more than 90% of patients who never received any treatment responded to therapy. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that weakens muscles, impacts physical function, and causes irreversible brain and spinal cord damage. To date, only 2 products are approved for slowing the functional decline associated with ALS. The accelerated clinical trials for developing new products targeting ALS are in progress. For example, antisense oligonucleotides (ASOs) have been showing promising results in clinical trials involving patients suffering from ALS. Further, different gene therapy approaches, targeting multiple mutations in patients for both sporadic ALS and familial ALS, are in clinical trials. Thus, clinical trials of an extensive pipeline of biopharmaceuticals are expected to offer lucrative growth opportunities to the Middle East & Africa biopharmaceuticals market in the coming years.
The Middle East & Africa biopharmaceuticals market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Saudi Arabia is expected to account for the largest market share and is expected to develop moderately in the Middle East & Africa during the forecast period. This is mainly due to Saudi Arabia's Ministry signing MOM or agreement with biotech companies to establish a production facility in the country. For example, Saudi Arabia's Ministry of Investment (MISA) and clinical-stage AI-driven drug discovery company Insilico Medicine announced signing a memorandum of understanding (MOU) to support the development of the AI-driven biotech industry in the KSA. Additionally, Merck KGaA announced a signing agreement with SaudiVax of Saudi Arabia to design and construct a multimodality biologic manufacturing facility to promote localized production infrastructure in the Middle East & Africa.
Saudi Arabia is the most significant pharmaceutical market in the Middle East due to increasing gross domestic product (GDP) and is ranked in the top 30 worldwide. It is an encouraging market for biopharmaceuticals firms. For instance, Aurobindo started investing in Saudi Arabia by producing medicines to treat chronic diseases such as diabetes, heart disease, and hypertension. Likewise, many top biopharmaceuticals firms are planning to set up a production base in the UAE. For example, AstraZeneca announced the expansion of its partnership with AI-based company G42 Healthcare by signing an agreement to manufacture innovative drugs in Abu Dhabi. The agreement focuses on collaboration in four key areas—localizing innovative industries, R&D, innovation, and sustainability—to promote the UAE as a hub for future industries.
Middle East & Africa Biopharmaceuticals Market Segmentation
The Middle East & Africa biopharmaceuticals market is segmented into product type, application, and country.
Based on product type, the Middle East & Africa biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the Middle East & Africa biopharmaceuticals market.
The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.
Based on application, the Middle East & Africa biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the Middle East & Africa biopharmaceuticals market.
Based on country, the Middle East & Africa biopharmaceuticals market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2022, Saudi Arabia held the largest share of the Middle East & Africa biopharmaceuticals market.
AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, and Thermo Fisher Scientific Inc are among the leading companies operating in the Middle East & Africa biopharmaceuticals market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 13.36 Billion |
| Market Size by 2028 | US$ 28.81 Billion |
| CAGR (2022 - 2028) | 13.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East & Africa Biopharmaceuticals Market is valued at US$ 13.36 Billion in 2022, it is projected to reach US$ 28.81 Billion by 2028.
As per our report Middle East & Africa Biopharmaceuticals Market, the market size is valued at US$ 13.36 Billion in 2022, projecting it to reach US$ 28.81 Billion by 2028. This translates to a CAGR of approximately 13.7% during the forecast period.
The Middle East & Africa Biopharmaceuticals Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Biopharmaceuticals Market report:
The Middle East & Africa Biopharmaceuticals Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Biopharmaceuticals Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Biopharmaceuticals Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Biopharmaceuticals Market
